Devicor Medical Products, Neoprobe deal

Devicor will acquire Neoprobe's neoprobe GDS line of gamma detection device systems for $30 million in cash. Neoprobe will also be eligible for up to $20 million in royalties if Devicor achieves revenue from GDS products above $21 million during any fiscal year for up to five years. The GDS systems, which had 2010 sales of about $10 million, are marketed worldwide for intraoperative lymphatic mapping or sentinel lymph node biopsy. The deal, which is subject to Neoprobe shareholders' approval, is expected to close this month. ...